

IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF FLORIDA

CASE NO.: _____

_____)
PURDUE PHARMA L.P.,)
THE P.F. LABORATORIES, INC.,)
PURDUE PHARMACEUTICALS L.P.,)
RHODES TECHNOLOGIES,)
BOARD OF REGENTS OF THE UNIVERSITY OF)
TEXAS SYSTEM,)
and GRÜNENTHAL GMBH,)
)
Plaintiffs,)
)
v.)
)
WATSON LABORATORIES, INC. – FLORIDA,)
)
Defendant.)
_____)

COMPLAINT

Plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue
Pharmaceuticals L.P., Rhodes Technologies, Board of Regents of The University of Texas
System, and Grünenthal GmbH (collectively, “Plaintiffs”) hereby file their Complaint against
Defendant Watson Laboratories, Inc. – Florida (“Watson”), and allege as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement arising under the patent laws of
the United States, Title 35, United States Code.

THE PARTIES: PLAINTIFFS

2. Plaintiff Purdue Pharma L.P. (“Purdue Pharma”) is a limited partnership
organized and existing under the laws of the State of Delaware, having a place of business at One

Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901-3431. Purdue Pharma is an owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 18-20 below, an exclusive sublicensee of United States Patent No. 6,488,963 identified in paragraph 17 below, and an exclusive licensee of United States Patent No. 7,776,314 identified in paragraph 21 below. Purdue Pharma is also the holder of New Drug Application (“NDA”) No. 022272 for the controlled-release oxycodone pain-relief medication OxyContin[®], and is involved in the sales of OxyContin[®] in the United States.

3. Plaintiff The P.F. Laboratories, Inc. (“P.F. Labs”) is a corporation organized and existing under the laws of the State of New Jersey, having a place of business at 700 Union Boulevard, Totowa, NJ 07512. P.F. Labs is an owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 18-20 below, and is involved in the manufacture of controlled-release oxycodone pain-relief medication under the brand name OxyContin[®].

4. Plaintiff Purdue Pharmaceuticals L.P. (“Purdue Pharmaceuticals”) is a limited partnership organized and existing under the laws of the State of Delaware, having a place of business at 4701 Purdue Drive, Wilson, NC 27893. Purdue Pharmaceuticals is an owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 18-20 below, and is involved in the manufacture of controlled-release oxycodone pain-relief medication under the brand name OxyContin[®].

5. Plaintiff Rhodes Technologies (“Rhodes”) is a general partnership organized and existing under the laws of the State of Delaware, having a place of business at 498 Washington Street, Coventry, RI 02816. Rhodes is an owner of United States Patent Nos. 7,674,799, 7,674,800, and 7,683,072 identified in paragraphs 18-20 below, and is involved in the

manufacture of controlled-release oxycodone pain-relief medication under the brand name OxyContin®.

6. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes are associated companies.

7. Plaintiff Board of Regents of The University of Texas System (“University of Texas”) is an agency organized and existing under the laws of the State of Texas, having an address at 201 West 7th Street, Austin, TX 78701. University of Texas is the owner of United States Patent No. 6,488,963 identified in paragraph 17 below.

8. Plaintiff Grünenthal GmbH (“Grünenthal”) is a corporation organized and existing under the laws of Germany, having an address at 52078 Aachen, Zieglerstrasse 6, Germany. Grünenthal is the owner of United States Patent No. 7,776,314 identified in paragraph 21 below.

THE PARTIES: DEFENDANT

9. Upon information and belief, Defendant Watson Laboratories, Inc. – Florida is a corporation organized and existing under the laws of the State of Florida, having a registered address of 4955 Orange Drive, Davie, FL 33314 and its principal place of business at 4955 Orange Drive, Davie, FL 33314.

JURISDICTION AND VENUE

10. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

11. The patents identified below are the subject of pending litigation in the United States District Court for the Southern District of New York. Three of the five patents are at issue in actions filed in 2010, *Purdue Pharma L.P. et al. v. Ranbaxy Inc. et al.*, No. 10-civ-3734 (SHS) (S.D.N.Y. May 5, 2010) and *Purdue Pharma L.P. et al. v. Varam, Inc. et al.*, No. 10-

civ-6038 (SHS) (S.D.N.Y. Aug. 11, 2010), and have been associated with a multidistrict litigation also in the Southern District of New York, *In re OxyContin Antitrust Litigation*, No. 04-md-1603 (SHS) (S.D.N.Y. Apr. 23, 2004).

12. On March 23, 2011, Plaintiffs also filed complaints against three other would-be manufacturers of generic copies of OxyContin[®] in the Southern District of New York, including an action against Watson and its sister company Andrx Labs, LLC. *See Purdue Pharma L.P. et al. v. Watson Labs., Inc. – Florida & Andrx Labs LLC*, No. 11-civ-2036 (S.D.N.Y. Mar. 23, 2011) (the “Watson/Andrx action”); *Purdue Pharma L.P. et al. v. Actavis Elizabeth LLC*, No. 11-civ-2038 (S.D.N.Y. Mar. 23, 2011) (the “Actavis action”); *Purdue Pharma L.P. et al. v. Teva Pharms. USA, Inc.*, No. 11-civ-2037 (S.D.N.Y. Mar. 23, 2011) (the “Teva action”). The *Actavis* and *Watson/Andrx* actions involve all five patents listed below that are alleged to be infringed in this complaint. The *Teva* action involves four of the five patents listed below that are alleged to be infringed in this complaint.

13. Purdue contends, on information and belief, that jurisdiction and venue for this action are proper in the Southern District of New York. Before this action was filed, counsel for Purdue contacted counsel for Watson to discuss whether Watson would consent to jurisdiction in that Court. Watson’s response about New York was non-committal. Counsel for Watson would only state that Watson would agree to jurisdiction in Florida.

14. Under the Hatch-Waxman Act, to perfect Plaintiffs’ rights to a statutory 30-month stay of U.S. Food and Drug Administration (“FDA”) approval of Abbreviated New Drug Application (“ANDA”) No. 202352, Plaintiffs are required to bring suit within 45 days of their February 8, 2011 receipt of Watson’s Notice Letter described in paragraph 24 below. 21 U.S.C. § 355(j)(5)(B)(iii). On March 23, 2011, Plaintiffs filed the *Watson/Andrx* action in the

Southern District of New York. The allegations in the Complaint in that action are substantially identical to this Complaint with respect to Watson. Although Plaintiffs' choice of forum is the Southern District of New York, because Watson may challenge jurisdiction in that district, Plaintiffs are filing the present Complaint to ensure that suit has been timely commenced, regardless of how the Courts may later resolve motions challenging jurisdiction or venue in New York, if Watson were to bring such a motion.

15. This Court has personal jurisdiction over Watson because, *inter alia*, Watson has purposefully availed itself of the rights and benefits of the laws of this State and this Judicial District. Upon information and belief, Watson is a corporation organized and existing under the laws of this State, with a principal place of business in this State and this Judicial District. Watson does business in this State and this Judicial District, has engaged in continuous and systematic contact with this State and this Judicial District, and derives substantial revenue from things used or consumed in this State and this Judicial District. Upon information and belief, Watson engages in the manufacture and sale of a range of pharmaceutical products within and directed to the United States and this Judicial District specifically. In addition, upon information and belief, Watson is actively preparing to make the proposed generic copies of OxyContin[®] that are the subject of ANDA No. 202352, and to use, sell and offer for sale such generic copies in this State and this Judicial District.

16. Venue is proper in this Judicial District under 28 U.S.C. §§ 1391(b) and (c) and § 1400(b).

THE PATENTS IN SUIT

17. Plaintiff University of Texas is the lawful owner of all right, title and interest in United States Patent No. 6,488,963 entitled "HOT-MELT EXTRUDABLE PHARMACEUTICAL FORMULATION" ("the '963 patent"), including the right to sue and to

recover for past infringement thereof. Plaintiff University of Texas granted an exclusive license under the '963 patent to Abbott Laboratories, who in turn, granted an exclusive sublicense under that patent to Plaintiff Purdue Pharma. The '963 patent is listed in the FDA's "Orange Book" (*Approved Drug Products With Therapeutic Equivalence Evaluation*) as covering OxyContin[®], which is the subject of approved NDA No. 022272. A copy of the '963 patent is attached hereto as Exhibit A, which was duly and legally issued on December 3, 2002, naming James W. McGinity and Feng Zhang as the inventors.

18. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes are the lawful owners of all right, title and interest in United States Patent No. 7,674,799 entitled "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE" ("the '799 patent"), including all right to sue and to recover for past infringement thereof, which patent is listed in FDA's Orange Book as covering the drug OxyContin[®], which is the subject of approved NDA No. 022272. A copy of the '799 patent is attached hereto as Exhibit B, which was duly and legally issued on March 9, 2010, naming Robert Chapman, Lon S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

19. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes are the lawful owners of all right, title and interest in United States Patent No. 7,674,800 entitled "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE" ("the '800 patent"), including all right to sue and to recover for past infringement thereof, which patent is listed in the FDA's Orange Book as covering the drug OxyContin[®], which is the subject of approved NDA No. 022272. A copy of the '800 patent is attached hereto as Exhibit C, which was duly and legally issued on March 9, 2010, naming Robert Chapman, Lon S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

20. Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes are the lawful owners of all right, title and interest in United States Patent No. 7,683,072 entitled “OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE” (“the ’072 patent”), including all right to sue and to recover for past infringement thereof, which patent is listed in the FDA’s Orange Book as covering the drug OxyContin[®], which is the subject of approved NDA No. 022272. A copy of the ’072 patent is attached hereto as Exhibit D, which was duly and legally issued on March 23, 2010, naming Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, and Robert Kupper as the inventors.

21. Plaintiff Grünenthal is the lawful owner of all right, title and interest in United States Patent No. 7,776,314 entitled “ABUSE-PROOFED DOSAGE SYSTEM” (“the ’314 patent”), including the right to sue and to recover for past infringement thereof. Plaintiff Purdue Pharma is the exclusive licensee of the ’314 patent from Grünenthal, with the right to enforce the ’314 patent. The ’314 patent is listed in the FDA’s Orange Book as covering the drug OxyContin[®], which is the subject of approved NDA No. 022272. A copy of the ’314 patent is attached hereto as Exhibit E, which was duly and legally issued on August 17, 2010, naming Johannes Bartholomäus and Heinrich Kugelmann as the inventors.

DEFENDANT’S ANDA

22. Upon information and belief, Watson submitted ANDA No. 202352 to the FDA, under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)), seeking approval to engage in the commercial manufacture, use, sale, offer for sale or importation of generic oxycodone hydrochloride extended release tablets (“proposed generic copies of OxyContin[®]”) based on the Reference Listed Drug (“RLD”) OxyContin[®], which is the subject of approved NDA No. 022272, before the expiration of the ’963, ’799, ’800, ’072, and ’314 patents.

23. Upon information and belief, ANDA No. 202352 contains a “Paragraph IV” certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) alleging that the ’963, ’799, ’800, ’072, and ’314 patents, listed in the FDA’s Orange Book as covering the drug OxyContin[®], which is the subject of approved NDA No. 022272, are “invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, or sale of [the proposed generic copies of OxyContin[®]].”

24. In a letter dated February 7, 2011 addressed to Plaintiffs and received by Plaintiffs Purdue Pharma, P.F. Labs, Purdue Pharmaceuticals, and Rhodes on February 8, 2011, Watson provided “notice” with respect to its proposed generic copies of OxyContin[®] and the ’963, ’799, ’800, ’072, and ’314 patents under 21 U.S.C. § 355(j)(2)(B) (“Notice Letter”).

25. Watson’s submission of its ANDA was an act of infringement of the ’963, ’799, ’800, ’072, and ’314 patents under the United States Patent Law, 35 U.S.C. § 271(e)(2)(A).

26. Upon information and belief, Watson’s proposed generic copies of OxyContin[®] are covered by one or more claims of the ’963, ’799, ’800, ’072, and ’314 patents.

27. Upon information and belief, Watson’s commercial manufacture, use, sale, and/or offer for sale of the proposed generic copies of OxyContin[®] would infringe, contribute to the infringement of, and/or induce the infringement of one or more claims of the ’963, ’799, ’800, ’072, and ’314 patents.

28. Upon information and belief, Watson has been aware of the existence of the ’963, ’799, ’800, ’072, and ’314 patents, and has no reasonable basis for believing that the proposed generic copies of OxyContin[®] will not infringe the ’963, ’799, ’800, ’072, and ’314 patents, thus rendering the case “exceptional,” as that term is used in 35 U.S.C. § 285.

29. The acts of infringement by Watson set forth above will cause Plaintiffs

irreparable harm for which they have no adequate remedy at law, and will continue unless enjoined by this Court.

WHEREFORE, Plaintiffs pray for judgment:

A. Adjudging that Watson has infringed the '963, '799, '800, '072, and '314 patents, and that the commercial sale, offer for sale, use, and/or manufacture of the proposed generic copies of OxyContin[®] described in ANDA No. 202352 would infringe, induce infringement of, and/or contribute to the infringement of the '963, '799, '800, '072, and '314 patents;

B. Adjudging, pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any approval of ANDA No. 202352, under § 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)), to be a date not earlier than the dates of expiration of the '963, '799, '800, '072, and '314 patents plus any additional periods of exclusivity;

C. Preliminarily and permanently enjoining, pursuant to 35 U.S.C. §§ 271(e)(4)(B) and 283 and Rule 65, Fed. R. Civ. P., Watson, its officers, partners, agents, servants, employees, parents, subsidiaries, divisions, affiliate corporations, other related business entities and all other persons acting in concert, participation, or in privity with them, and their successors and assigns, from any commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of any drug product that infringes the '963, '799, '800, '072, and '314 patents;

D. Declaring this an exceptional case and awarding Plaintiffs their attorneys' fees, as provided by 35 U.S.C. §§ 271(e)(4) and 285; and

E. Awarding Plaintiffs such other and further relief as this Court may deem

just and proper.

Dated: March 24, 2011.

OF COUNSEL:

ROPES & GRAY LLP
Robert J. Goldman
robert.goldman@ropesgray.com
1900 University Ave., 6th Floor
East Palo Alto, CA 94303
Telephone: (650) 617-4000
Facsimile: (650) 617-4090

Pablo D. Hendler
Email: pablo.hendler@ropesgray.com
Sona De
Email: sona.de@ropesgray.com
1211 Avenue of the Americas
New York, NY 10036
Telephone: (212) 596-9000
Facsimile: (212) 596-9090

OF COUNSEL:

BANNER & WITCOFF, LTD.
Dale H. Hoscheit
Email: dhoscheit@bannerwitcoff.com
Joseph M. Skerpon
Email: jskerpon@bannerwitcoff.com
Robert F. Altherr
Email: raltherr@bannerwitcoff.com
1100 13th Street, NW, Suite 1200
Washington, DC 20005
Telephone: (202) 824-3000
Facsimile: (202) 824-3001

/s/ Patricia E. Lowry

Patricia E. Lowry
Florida Bar No. 332569
Email: patricia.lowry@ssd.com
Amy Bloom
Florida Bar No. 0506893
Email: amy.bloom@ssd.com
SQUIRE, SANDERS & DEMPSEY (US) LLP
1900 Phillips Point West
777 South Flagler Drive
West Palm Beach, FL 33401
Telephone: (561) 650-7200
Facsimile: (561) 655-1509

Attorneys for Plaintiffs
Purdue Pharma L.P.,
The P.F. Laboratories, Inc.,
Purdue Pharmaceuticals L.P.,
Rhodes Technologies, and
Board of Regents of The University of
Texas System

/s/ Scott W. Dangler

Scott W. Dangler
Florida Bar No. 0429007
Email: sdangler@gunster.com
GUNSTER
450 East Las Olas Boulevard
Suite 1400
Fort Lauderdale, FL 33301
Telephone: (954) 462-2000
Facsimile: (954) 523-1722
Attorneys for Plaintiff
Grünenthal GmbH